Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1999-03-19
2001-05-29
Navarro, Albert (Department: 1645)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S252300, C435S320100, C435S325000, C536S023700
Reexamination Certificate
active
06238887
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of the ribosome recycling factor family, as well as their variants, hereinafter referred to as “frr,” “frr polynucleotide(s), ” and “frr polypeptide(s)” as the case may be.
BACKGROUND OF THE INVENTION
It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics. The Staphylococci make up a medically important genera of microbest. They are known to produce two types of disease, invasive and toxigenic. Invasive infections are characterized generally by abscess formation effecting both skin surfaces and deep tissues.
S. aureus
is the second leading cause of bacteremia in cancer patients. Osteomyelitis, septic arthritis, septic thrombophlebitis and acute bacterial endocarditis are also relatively common. There are at least three clinical conditions resulting from the toxigenic properties of Staphylococci. The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia. These conditions include: Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome.
The frequency of
Staphylococcus aureus
infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Staphylococcus aureus
strains which are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new antimicrobial agents, vaccines, drug screening methods, and diagnostic tests for this organism.
Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces “functional genomics,” that is, high throughout genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on “positional cloning” and other methods. Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery.
Ribosome recycling (releasing) factor is a protein that is responsible for dissociation of ribosomes from mRNA after termination of translation (Janosi, L., Hara. Zhang S. & Kaji (1996) Ribosome recycling by ribosome recycling factor (RRF). An important but overlooked step of protein synthesis.
Advances in Biophysics
32:121-201). In the final steps of protein biosynthesis the termination-codon specific peptide-chain release factor releases a nascent complete peptide chain from peptidyl tRNA. The resulting complex of ribosome, mRNA, and the tRNA must be recycled for the next round of protein synthesis. Thus the ribosome releasing factor working together with GTP and elongation factor G dissociates this complex into tRNA, ribosome and mRNA. The protein has also been shown to prevent translational errors and is therefore involved in peptide elongation (Janosi L, Ricker R & Kaji A (1996) Dual functions of ribosome recycling factor in protein biosynthesis: disassembling the termination complex and preventing translational errors.
Biochimie
78:959-969). The discovery of a
Staphylococcus aureus
gene encoding a ribosome recycling factor-like protein which is expressed in vivo implies that there is a role for this protein during infection.
Clearly, there exists a need for polynucleotides and polypeptides, such as the frr embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antimicrobial activity. Such factors are also useful to determine their role in pathogenesis of infection dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
SUMMARY OF THE INVENTION
The present invention relates to frr, in particular frr polypeptides and frr polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including treatment of microbial diseases, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists using the materials provided by the invention, and for treating microbial infections and conditions associated with such infections with the identified agonist or antagonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting frr expression or activity.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
REFERENCES:
patent: 786519 (1997-07-01), None
Lowe, et al., “Staphylococcus aureusribosome recycling factor (frr) gene, complete cds.”, GenBank Submission, Accession No. AF033018, Nov. 27, 1997.
Phillips, et al., “Proline Iminopeptidase (fragment)”, GenBank Submission, Accession No. 031202, Jan. 1, 1998.
Janosi, et al., “Dual functions of ribosime recycling factor in protein biosynthesis: Disassembling the termination complex and preventing tanslational errors”, Biochimie, vol. 78, pp. 959-969, (1996).
Janosi, et al., “Ribosome Recycling by Ribosome Recycling Factor (RRF)—An Important but Overlooked Step of Protein Biosynthesis”, Adv. Biophys., vol. 32, pp. 121-201, (1996).
Beattie David T
Deresiewicz Robert L
Hodgson John E
Lonetto Michael A
Lowe Adrian M
Brigham & Women's Hospital
Deibert Thomas S.
Gimmi Edward R.
King William T.
Navarro Albert
LandOfFree
Ribosome recycling factor (FRR) of Staphylococcus aureus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ribosome recycling factor (FRR) of Staphylococcus aureus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ribosome recycling factor (FRR) of Staphylococcus aureus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2462821